Abstract
In some parts of the world, medicinal cannabinoids have already been used to treat nausea and vomiting associated with chemotherapy and wasting in diseases such as AIDS and terminal cancer. However, over the last several years, currently used cannabinoids, such as dronabinol, as well as newly developed cannabis-based medicines such as Sativex® (narrow ratio combination of Δ9-tetrahydrocannabinol and cannabidiol), have been investigated for the treatment of spasticity, chronic pain, disruption of sleep and urinary dysfunction associated with multiple sclerosis and other neurological disorders. Although some clinical trials have yielded positive results, others have not and there has been controversy regarding the use of subjective rating scales to measure pain and spasticity. Adverse side effects have been generally mild and transient; however, researchers and clinicians are still concerned about the prospect of long-term adverse side effects. This review will summarise and critically evaluate the currently available clinical trial data.
Keywords: Cannabinoids, cannabis, multiple sclerosis, pain, spasticity
Current Drug Therapy
Title: Will Medicinal Cannabinoids Prove to be Useful Clinically?
Volume: 2 Issue: 2
Author(s): Paul F. Smith
Affiliation:
Keywords: Cannabinoids, cannabis, multiple sclerosis, pain, spasticity
Abstract: In some parts of the world, medicinal cannabinoids have already been used to treat nausea and vomiting associated with chemotherapy and wasting in diseases such as AIDS and terminal cancer. However, over the last several years, currently used cannabinoids, such as dronabinol, as well as newly developed cannabis-based medicines such as Sativex® (narrow ratio combination of Δ9-tetrahydrocannabinol and cannabidiol), have been investigated for the treatment of spasticity, chronic pain, disruption of sleep and urinary dysfunction associated with multiple sclerosis and other neurological disorders. Although some clinical trials have yielded positive results, others have not and there has been controversy regarding the use of subjective rating scales to measure pain and spasticity. Adverse side effects have been generally mild and transient; however, researchers and clinicians are still concerned about the prospect of long-term adverse side effects. This review will summarise and critically evaluate the currently available clinical trial data.
Export Options
About this article
Cite this article as:
Smith F. Paul, Will Medicinal Cannabinoids Prove to be Useful Clinically?, Current Drug Therapy 2007; 2 (2) . https://dx.doi.org/10.2174/157488507780619059
DOI https://dx.doi.org/10.2174/157488507780619059 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anti-VEGF Treatment in Corneal Diseases
Current Drug Targets Vitamins in Heart Failure: Friend or Enemy?
Current Pharmaceutical Design Endothelial Function in Renal Transplant Recipients is Associated with Circulating Nitric Oxide, ACE Inhibitor Use and Time After Transplantation
Vascular Disease Prevention (Discontinued) Lifestyle Factors and Endothelial Function
Current Vascular Pharmacology Role of Adiponectin in Obesity, Hypertension, and Metabolic Syndrome
Current Hypertension Reviews Thyrotoxic Periodic Paralysis: A Concise Review of the Literature
Current Rheumatology Reviews The Effect of Serotonin 5-HT2 Receptor Inhibitor on Vasomotor Responses
Vascular Disease Prevention (Discontinued) Effect of Androgenic and Antiandrogenic Acting Compounds in Macrophage Accumulation and Cell Replication in the Aorta of Oophorectomized Hypercholesterolemic Rabbits
Vascular Disease Prevention (Discontinued) Design and Development of Novel Azo Prodrugs using Various Permutations and Combinations of 5- and 4-Aminosalicylic Acids for Inflammatory Bowel Disease: A Colon-Targeted Approach
Inflammation & Allergy - Drug Targets (Discontinued) The Role of Heat Shock Protein 90 and Endothelial Nitric Oxide Synthase Signaling in Cardiovascular Therapy
Current Signal Transduction Therapy Imaging Patterns of Cardiovascular Involvement in Mixed Connective Tissue Disease Evaluated by Cardiovascular Magnetic Resonance
Inflammation & Allergy - Drug Targets (Discontinued) Non-Invasive Diagnostic Tools for Investigating Endothelial Dysfunction
Current Pharmaceutical Design Vascular Effects of Insulin and Their Relation to Endothelial Dysfunction, Insulin Resistance and Hypertension
Current Hypertension Reviews Topiramate in the New Generation of Drugs: Efficacy in the Treatment of Alcoholic Patients
Current Pharmaceutical Design PET Molecular Imaging of Hypoxia in Ischemic Stroke: An Update
Current Vascular Pharmacology Measurement of Physical Changes in the Myocardium for Development of Novel Methods for Diagnosing Ischemia
Current Cardiology Reviews Lack of Evidence for Deterioration in Endothelial Function Following Ticagrelor Treatment Cessation
Current Vascular Pharmacology Adenosine A<sub>2A</sub> Receptor Antagonists as Positron Emission Tomography (PET) Tracers
Current Medicinal Chemistry The Role of Ultrasonography of Peripheral Entheses in the Diagnosis and Assessment of Spondyloarthropathies
Current Rheumatology Reviews Stable Angina Pectoris: Current Medical Treatment
Current Pharmaceutical Design